Trevi Therapeutics, Inc. (TRVI )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol TRVI
- Company Trevi Therapeutics, Inc.
- Price $17.48
- Changes Percentage 4.23
- Change 0.71
- Day Low $17.01
- Day High $17.51
- Year High $16.12
- Year Low $5.41
- Market Cap $1,909,627,073
- Price Avg 50 EMA (D) $13.64
- Price Avg 200 EMA (D) $11.41
- Exchange NASDAQ
- Volume 703,621
- Average Volume 1,482,524
- Open $17.15
- Previous Close $16.77
- EPS -0.32
- PE -42.03
- Earnings Announcement 2026-08-06 04:00:00
- Shares Outstanding $141,979,708
Company brief: TREVI THERAPEUTICS, INC. (TRVI )
- Healthcare
- Biotechnology
- Ms. Jennifer L. Good
- https://www.trevitherapeutics.com
- US
- N/A
- 05-07-2019
- US89532M1018
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.